MiR-146a regulates the TRAF6/TNF-axis in donor T cells during GVHD.

Acute graft-versus-host disease (GVHD) limits the success of allogeneic hematopoietic cell transplantation (allo-HCT); therefore, a better understanding of its biology may improve therapeutic options. We observed miR-146a up-regulation in T cells of mice developing acute GVHD compared with untreated mice. Transplanting miR-146a(-/-) T cells caused increased GVHD severity, elevated tumor necrosis factor (TNF) serum levels, and reduced survival. TNF receptor-associated factor 6 (TRAF6), a verified target of miR-146a, was up-regulated in miR-146a(-/-) T cells following alloantigen stimulation. Higher TRAF6 levels translated into increased nuclear factor-κB activity and TNF production in miR-146a(-/-) T cells. Conversely, the detrimental effect of miR-146a deficiency in T cells was antagonized by TNF blockade, whereas phytochemical induction of miR-146a or its overexpression using a miR-146a mimic reduced GVHD severity. In humans, the minor genotype of the single nucleotide polymorphism rs2910164 in HCT donors, which reduces expression of miR-146a, was associated with severe acute GVHD (grade III/IV). We show that miR-146a functions as a negative regulator of donor T cells in GVHD by targeting TRAF6, leading to reduced TNF transcription. Because miR-146a expression can be exogenously enhanced, our results provide a novel targeted molecular approach to mitigate GVHD.

[1]  S. Atarod,et al.  MicroRNAs: The Missing Link in the Biology of Graft-Versus-Host Disease? , 2013, Front. Immunol..

[2]  C. Ross,et al.  Atypical E2F Dependent Dysregulation Of Cell Cycling By Microrna-142 Regulates T-Cell Responses and Experimental Graft-Versus-Host Disease , 2013 .

[3]  J. Karrich,et al.  MicroRNA-146a regulates survival and maturation of human plasmacytoid dendritic cells. , 2013, Blood.

[4]  Lifang Jiang,et al.  miR-146a facilitates replication of dengue virus by dampening interferon induction by targeting TRAF6. , 2013, The Journal of infection.

[5]  D. Iliopoulos,et al.  MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. , 2013, Gastroenterology.

[6]  M. Idzko,et al.  The Nlrp3 inflammasome regulates acute graft-versus-host disease , 2013, The Journal of experimental medicine.

[7]  F. Bazzoni,et al.  Negative regulation of Toll-like receptor 4 signaling by IL-10–dependent microRNA-146b , 2013, Proceedings of the National Academy of Sciences.

[8]  Ryan M. O’Connell,et al.  MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice , 2013, eLife.

[9]  S. Grundmann,et al.  Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100. , 2013, Blood.

[10]  A. Vaiopoulou,et al.  Association Study of Genetic Variants in miRNAs in Patients with Inflammatory Bowel Disease: Preliminary Results , 2013, Digestive Diseases and Sciences.

[11]  J. Wedemeyer,et al.  MicroRNA-146a-mediated downregulation of IRAK1 protects mouse and human small intestine against ischemia/reperfusion injury , 2012, EMBO molecular medicine.

[12]  L. Orozco,et al.  MiR-146a polymorphism is associated with asthma but not with systemic lupus erythematosus and juvenile rheumatoid arthritis in Mexican patients. , 2012, Tissue antigens.

[13]  Scott E. Smith,et al.  TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  D. Baltimore,et al.  miR-146a controls the resolution of T cell responses in mice , 2012, The Journal of experimental medicine.

[15]  Bruce R. Blazar,et al.  Advances in graft-versus-host disease biology and therapy , 2012, Nature Reviews Immunology.

[16]  L. Truedsson,et al.  Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene , 2012, Genes and Immunity.

[17]  N. Yamashita,et al.  Profiling of immune‐related microRNA expression in human cord blood and adult peripheral blood cells upon proinflammatory stimulation , 2012, European journal of haematology.

[18]  C. McCall,et al.  MicroRNA‐146a regulates both transcription silencing and translation disruption of TNF‐α during TLR4‐induced gene reprogramming , 2011, Journal of leukocyte biology.

[19]  M. Caligiuri,et al.  Regulation of acute graft-versus-host disease by microRNA-155. , 2010, Blood.

[20]  David Baltimore,et al.  Function of miR-146a in Controlling Treg Cell-Mediated Regulation of Th1 Responses , 2010, Cell.

[21]  F. Sarkar,et al.  A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. , 2010, American journal of translational research.

[22]  A. Arslan,et al.  Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. , 2010, Gynecologic oncology.

[23]  Zhiwei Wang,et al.  miR-146a suppresses invasion of pancreatic cancer cells. , 2010, Cancer research.

[24]  K. Akashi,et al.  Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. , 2009, Blood.

[25]  Barbara Jarzab,et al.  Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma , 2008, Proceedings of the National Academy of Sciences.

[26]  Christopher G. King,et al.  Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity. , 2007, Blood.

[27]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[28]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[29]  P. Lipsky,et al.  TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. , 2006, Blood.

[30]  Christopher H Contag,et al.  Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. , 2006, Blood.

[31]  D. Jain,et al.  Target Antigens Determine Graft-versus-Host Disease Phenotype , 2004, The Journal of Immunology.

[32]  Zhijian J. Chen,et al.  The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. , 2004, Molecular cell.

[33]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[34]  M. V. D. van den Brink,et al.  Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. , 2003, Blood.

[35]  J. Crawford,et al.  LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. , 2001, The Journal of clinical investigation.

[36]  J. Crawford,et al.  Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft versus leukemia , 1999 .

[37]  R. Storb,et al.  Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. , 1974, Transplantation proceedings.

[38]  J. Mary,et al.  Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression. , 2004, Blood.

[39]  J. Crawford,et al.  Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. , 1999, The Journal of clinical investigation.

[40]  M. Remberger,et al.  TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. , 1995, Bone marrow transplantation.

[41]  P. Linsley,et al.  miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice , 2011, The Journal of experimental medicine.